Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more than 1,200 lawyers located in 16 offices worldwide, our client-centered approach is grounded in nearly a century of building enduring relationships on trust and collaboration. Our broad and diversified practices serve global clients—from startups to Fortune 500 companies—at every stage of the business cycle, including high-stakes litigation, complex transactions, sophisticated financings and regulatory issues. With leading edge technologies and innovation behind our team, we pride ourselves on being a strategic partner to our clients.
This webinar will discuss key changes to the Medicare Advantage and Part D programs that are contained in CMS' proposed rule published on December 10, 2024.
United StatesFood, Drugs, Healthcare, Life Sciences
Christine M. Clements’s articles from Sheppard, Mullin, Richter & Hampton LLP are most popular:
within Food, Drugs, Healthcare and Life Sciences topic(s)
in Europe
Sheppard, Mullin, Richter & Hampton LLP are most popular:
within Cannabis & Hemp topic(s)
This webinar will discuss key changes to the Medicare Advantage
and Part D programs that are contained in CMS' proposed rule
published on December 10, 2024, including proposed changes related
to Star Ratings, marketing and communications, agent/broker
compensation, health equity, drug coverage, D-SNPs, utilization
management, artificial intelligence, network adequacy, and other
programmatic areas.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
